Rapid Molecular Diagnostics

Six years of research has led to a diagnostic capability that will allow the US to fully open up for business and recreation. It is a can be used to rapidly test large numbers of people for COVID-19 with a test that is fast, accurate, inexpensive, and coming soon.


Our Advantages

The RMD testing for COVID-19 has the following Advantages:
  • Extremely Fast Sample collection and preparation

  • Extremely Fast Analysis

  • Cost Effective: Sample and Reagents less than $5 per Test

  • Automated, High Volume Processing

  • Uses Existing Equipment

Back to Top

Applications

The RMD testing for COVID-19 could be used for:
  • Testing people at airports

  • Screening people entering sporting events

  • Screening visitors at nursing homes

Back to Top
Consider the case of DFW Airport

There are approximately 1850 flights that leave DFW on an average day carrying roughly 500,000 passengers.

With our diagnostic tools in security checkpoints we could process all passengers at a combined rate of ~50 tests per minute. Passengers that test positive could be identified and quarantined. The other passengers could travel without the concern of being infected by COVID-19.


Our Technology

Back to Top
RMD technology is dramatically different from other diagnostic processes that are time consuming and/or expensive. By placing testing for COVID-19 genetic material with a fast, and inexpensive test we can deliver an accurate diagnosis in minutes.
  

About US

Back to Top
Rapid Molecular Diagnostics is a new company, but it springs from two very innovative companies and one remarkable physician.

Biological Mimetics, Inc. This remarkable company has developed:

  • Bioinformatics-based probe design
  • DNA-RNA hybridization conditions
  • Rational antigen design methods for deriving broadly protective vaccines
  • Two clinical stage spin-off companies.
    • Lantern Pharma, Inc. which is developing cancer therapeutics using AI-based precision medicine algorithms.
    • Keystone Bio, Inc. which is developing antibody treatments and preventatives for Alzheimer's and cardiac diseases.
Zyvex Labs This nanotechnology company has developed:
  • Atomically precise fabrication equipment used in Quantum Research for fabricating solid state devices,
  • An artificial retina for which a joint venture company has started human clinical trials in Europe
  • A spin-off company that has two Early feasibility studies approved for neuromodulation implants
Gerhard Maale MD Has innovated medical treatments, devices, and methods in:
  • Orthopedic Oncology, Pathology, Complex Total Joint Reconstructions, and Musculoskeletal Infections
  • Bioengineering for Upper and Lower Extremity Total Joint Revisions
  • Molecular Diagnostics
  • DNA and RNA Biochemistry - Gene Cancer Detections
  • Microbiology and Virology
  • Local Molecular Biodegradable Carriers for Antibiotics and Cancer Drugs
  • Biofilm Engineering

Rapid Molecular Diagnostic Founders:

     
Dr. Greg Tobin
Dr. Tobin, RMD's CEO, has led research and technical programs at BMI since 1999. Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; personnel management; coordination of multi-site studies and development of research facilities. Dr. Tobin fosters a highly interactive research and development group to apply the Company’s proprietary technology, Immune Refocusing Technology, to the design of antigens that induce broader protection against heterologous challenge. Dr. Tobin continues to maintain research projects and interests in the development of broadened vaccines against human rhinovirus, RSV, poliovirus, influenza virus, HIV-1, and Acinetobacter baumannii. Dr. Tobin is currently the Principal Investigator on two active NIH SBIR grants and one STTR contract at DTRA.

Prior to joining BMI, Dr. Tobin was a Senior Scientist and Group Leader (Gene Expression Regulation Group) for SAIC-Frederick at the National Cancer Institute. While at the NCI, Dr. Tobin led projects related to development of virus-like particle (VLP) based vaccines for HIV-1, optimization of recombinant protein expression, development of animal models for AIDS and cancer, and investigations into the pathobiology and molecular mechanisms of bovine immunodeficiency virus (BIV) and visna virus. Dr. Tobin was a post-doctoral scientist applying transgenic mouse models to the understanding of oncogenesis in the laboratory of Dr. Terry Van Dyke. During his doctoral research, Dr. Tobin studied the replication of poliovirus with Dr. J. Bert Flanegan at the University of Florida. Prior to graduate studies, Dr. Tobin gained valuable insight into virology and research methods in the University of Virginia laboratory of Dr. Jay C. Brown and William W. Newcomb.


Rahul, RMD's VP of Engineering, joined Zyvex in 2001 to work on scaling down macro and meso size devices using MEMS and assembly. In this endeavor, Rahul has been PI on four DARPA programs to build the world’s smallest electron column, the World's smallest ion microcolumn, the system integrator for a brain stimulation and recording instrument, and the developer of an implant for acute sensing during the critical phase of spinal cord injuries respectively. He is also the Director of MEMS, Nano Retina Inc and the system architect for Bionic Eye-NR600, an innovation to heal the blind. Rahul has over 25 published articles and more than 10 patents awarded/pending in his name. He is currently working on next generation Class III compliant neural transducers and, as adjunct faculty at University of Texas at Arlington, he has taught advanced Graduate level courses in MEMS and MEMS design.

In August 2018, Rahul Saini was awarded the Tech Titans Technology Inventors award.This award recognizes the pioneering accomplishments of a person, team or group responsible for the creation of breakthrough ideas, processes or products which have advanced the discipline(s) of the arts, education, electronics, energy, engineering, environment, medicine, and/or science. He was primarily recognized for his work on the NR-600 bionic eye.

Rahul has a BTech in Aerospace Engineering (1998) from the Indian Institute of Technology, Mumbai and an MS in Aerospace and Engineering Mechanics ( 2001) from the University of Florida.


     
Rahul Saini
     
Gerhard Maale M.D.
Dr. Gerhard Maale is the medical director of orthopedic oncology and leads the Complex Joints and Musculoskeletal Tumors Program at the Dallas Forth Worth Sarcoma Group. He has more than 35 years of experience performing complex joint reconstructions and treating bone and soft tissue disorders, bone disease, and musculoskeletal infections. After graduating from the University of Florida School of Medicine, he completed his orthopedic surgery residency at the University of Virginia and an orthopedic oncology fellowship at the University of Florida. Dr. Maale has also published work in international journals has six issued US patents and 7 patents pending.

Dr. Maale is the Founder of Dallas Ft. Worth Sarcoma Group, the Director of Orthopedic Oncology, Medical City Plano, Texas, and the Director of Sara Canon Initiative for Sarcoma HCA Hospitals. He previous posiitons include: Associate Professor, Department of Orthopedic Surgery, Texas Tech University School of Medicine, Associate Professor, Department of Pathology, Texas Tech University School of Medicine, Director, Orthopedic Oncology Fellowship, University of Texas Southwestern Medical School, Dallas, Texas, and President, Dallas/Fort Worth Texas branch of Western Orthopedic Association, His many honors include: Recipient of the Journal of Trauma Residents’ Award for the Northeast Regional Competition for NIH and NCI sponsored for Oncology Fellowship, Recipient of the State of Texas House of Representatives Certificate of Appreciation for Outstanding Contributions to the Fight Against Cancer, Teaching Excellence Award-Southwestern Orthopedic Residents, and Texas Tech health Science Center, El Paso, Texas Certificate of Appreciation.


Matthew, RMD's Director of Research and Development, joined Zyvex Labs in May of 2015 as a mechanical engineering intern. He showed great interest in the blend of semiconductor technology and modern medicine. He has since been part of the Micro and Biosystems department and has worked on multiple projects enabling various biotechnology platforms and devices. Matt is pursuing his Masters in Biomedical Engineering at the University of Texas at Dallas (UTD) and in parallel he is the lead engineer on the development of Zyvex’s Rapid Molecular Diagnostic (RMD) platform. He has worked in the Nanostructure Surface Modification lab at UTD to enable the feasibility of RMD system design.

Matthew received his B.S. in Mechanical Engineering from Texas Tech University in December, 2016 and looks forward to finishing his Masters by the end of Fall 2020.


     
Matt Maale
     
John Randall
John, Chief Strategy Officer of RMD, joined Zyvex Labs in March, 2001. Prior to Zyvex, John spent 15 years with Texas Instruments (TI) where he worked in high resolution processing for integrated circuits, MEMS, and quantum effect devices and also worked at MIT’s Lincoln Laboratory on ion beam and x-ray lithography. John is Executive VP at NanoRetina and currently lends his 30+ years of experience in micro- and nano-fabrication to his roles as Adjunct Professor at UT Dallas and Fellow of the AVS, IEEE, and Micro Nano Engineering Society. He has attracted over $43M in research contracts to Zyvex and resulting products have grossed over $80M. John has 114 published articles, more than 50 conference proceedings and other publications (>4200 citations) and 32 issued US Patents (>800 citations).

John has a B.S. (1975), M.S. (1977), PhD (1981) in Electrical Engineering from the University of Houston.



Rapid Molecular Diagnostics LLC

1301 North Plano Road
Richardson, Texas, 75081

Contact us at: info@rapidmoleculardiagnostics.com

Back to Top